Jinahn Jeong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jinahn Jeong has a total of 470 co-authors. Here are the top co-authors by number of shared publications:
- Bokyung Ahn
Department of pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
2 shared publications - Ja-Min Park
Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2 shared publications - Sun Young Yoon
Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2 shared publications - Yong Il Lee
Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2 shared publications - Yong Mee Cho
Department of pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
2 shared publications A. Gmerek
1 shared publication
Latest Publications
- Open Access
- 15 September 2024
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 58 (5) , 229-240
Artificial intelligence algorithm for neoplastic cell percentage estimation and its application to copy number variation in urinary tract cancer
Background: Bladder cancer is characterized by frequent mutations, which provide potential therapeutic targets for most patients. The effectiveness of emerging personalized therapies depends on an accurate molecular diagnosis, for which the accurate estimation of the neoplastic cell percentage (NCP) is a crucial initial step. However, the established method for determining the NCP, manual counting by a pathologist, is time-consuming and not easily executable. Methods: To address this, artificial intelligence (AI) models were developed to estimate the NCP using nine convolutional neural networks and the scanned images of 39 cases of urinary tract cancer. The performance of the AI models was compared to that of six pathologists for 119 cases in the validation cohort. The ground truth value was obtained through multiplexed immunofluorescence. The AI model was then applied to 41 cases in the application cohort that underwent next-generation sequencing testing, and its impact on the copy number variation (CNV) was analyzed. Results: Each AI model demonstrated high reliability, with intraclass correlation coefficients (ICCs) ranging from 0.82 to 0.88. These values were comparable or better to those of pathologists, whose ICCs ranged from 0.78 to 0.91 in urothelial carcinoma cases, both with and without divergent differentiation/ subtypes. After applying AI-driven NCP, 190 CNV (24.2%) were reclassified with 66 (8.4%) and 78 (9.9%) moved to amplification and loss, respectively, from neutral/minor CNV. The neutral/minor CNV proportion decreased by 6%. Conclusions: These results suggest that AI models could assist human pathologists in repetitive and cumbersome NCP calculations.
- 15 September 2024
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 58 (5) , 229-240
Open AccessArtificial intelligence algorithm for neoplastic cell percentage estimation and its application to copy number variation in urinary tract cancer
Background: Bladder cancer is characterized by frequent mutations, which provide potential therapeutic targets for most patients. The effectiveness of emerging personalized therapies depends on an accurate molecular diagnosis, for which the accurate estimation of the neoplastic cell percentage (NCP) is a crucial initial step. However, the established method for determining the NCP, manual counting by a pathologist, is time-consuming and not easily executable. Methods: To address this, artificial intelligence (AI) models were developed to estimate the NCP using nine convolutional neural networks and the scanned images of 39 cases of urinary tract cancer. The performance of the AI models was compared to that of six pathologists for 119 cases in the validation cohort. The ground truth value was obtained through multiplexed immunofluorescence. The AI model was then applied to 41 cases in the application cohort that underwent next-generation sequencing testing, and its impact on the copy number variation (CNV) was analyzed. Results: Each AI model demonstrated high reliability, with intraclass correlation coefficients (ICCs) ranging from 0.82 to 0.88. These values were comparable or better to those of pathologists, whose ICCs ranged from 0.78 to 0.91 in urothelial carcinoma cases, both with and without divergent differentiation/ subtypes. After applying AI-driven NCP, 190 CNV (24.2%) were reclassified with 66 (8.4%) and 78 (9.9%) moved to amplification and loss, respectively, from neutral/minor CNV. The neutral/minor CNV proportion decreased by 6%. Conclusions: These results suggest that AI models could assist human pathologists in repetitive and cumbersome NCP calculations.
- Open Access
- 31 July 2024
- Published by Korean Urological Oncology Society in Journal of Urologic Oncology
- Vol. 22 (2) , 115-127
Pathologic Diagnosis of Renal Cell Carcinoma in the Era of the 2022 World Health Organization Classification: Key Points for Clinicians
The remarkable advances in our understanding of renal tumor pathogenesis, driven by the widespread application of molecular testing, are reflected in the latest 2022 World Health Organization classification. This updated classification categorizes renal cell carcinoma (RCC) into morphologically and molecularly defined RCCs. It includes updates to existing entities and introduces newly established and provisional entities. A standard macroscopic and microscopic evaluation is typically sufficient for diagnosing morphologically defined RCCs and serves as the initial step in the identification of molecularly defined entities. In cases where classification based solely on histologic examination is challenging, a limited panel of immunohistochemical stains can be employed to aid in the diagnosis, with molecular testing for validation if necessary. Therefore, this review explores the key clinical, pathological, and molecular features essential for classifying both the commonly encountered morphologically defined RCCs and the less common but clinically significant molecularly defined RCCs. The goal is to increase awareness of these RCC subtypes among clinicians and promote a deeper understanding of the pathological diagnostic process, ultimately improving patient care.
- 31 July 2024
- Published by Korean Urological Oncology Society in Journal of Urologic Oncology
- Vol. 22 (2) , 115-127
Open AccessPathologic Diagnosis of Renal Cell Carcinoma in the Era of the 2022 World Health Organization Classification: Key Points for Clinicians
The remarkable advances in our understanding of renal tumor pathogenesis, driven by the widespread application of molecular testing, are reflected in the latest 2022 World Health Organization classification. This updated classification categorizes renal cell carcinoma (RCC) into morphologically and molecularly defined RCCs. It includes updates to existing entities and introduces newly established and provisional entities. A standard macroscopic and microscopic evaluation is typically sufficient for diagnosing morphologically defined RCCs and serves as the initial step in the identification of molecularly defined entities. In cases where classification based solely on histologic examination is challenging, a limited panel of immunohistochemical stains can be employed to aid in the diagnosis, with molecular testing for validation if necessary. Therefore, this review explores the key clinical, pathological, and molecular features essential for classifying both the commonly encountered morphologically defined RCCs and the less common but clinically significant molecularly defined RCCs. The goal is to increase awareness of these RCC subtypes among clinicians and promote a deeper understanding of the pathological diagnostic process, ultimately improving patient care.
- Open Access
- 1 May 2012
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 27 (suppl 2) , ii197-ii226
Extracorporeal dialysis: techniques and adequacy
Introduction and Aims: There is no consensus on the best method to quantify hemodialysis and the optimal dosage of hemodialysis. Urea is the substance most often measured as a surrogate for the clearance of small molecules. In particular, Kt/V, that is the dialyzer clearance of urea, multiplied by the length of the dialysis session, divided by the volume of distribution of urea, is the most widely accepted indicator of adequacy of hemodialysis. Most commonly Kt/V is estimated, by means of Daugirdas formula, from the values of BUN (postdialysis/predialysis), ultrafiltration volume and postdialysis body weight.
- 1 May 2012
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 27 (suppl 2) , ii197-ii226
Open AccessExtracorporeal dialysis: techniques and adequacy
Introduction and Aims: There is no consensus on the best method to quantify hemodialysis and the optimal dosage of hemodialysis. Urea is the substance most often measured as a surrogate for the clearance of small molecules. In particular, Kt/V, that is the dialyzer clearance of urea, multiplied by the length of the dialysis session, divided by the volume of distribution of urea, is the most widely accepted indicator of adequacy of hemodialysis. Most commonly Kt/V is estimated, by means of Daugirdas formula, from the values of BUN (postdialysis/predialysis), ultrafiltration volume and postdialysis body weight.